112 related articles for article (PubMed ID: 22032838)
21. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
[TBL] [Abstract][Full Text] [Related]
22. Patient satisfaction and cancer-related distress among unselected Jewish women undergoing genetic testing for BRCA1 and BRCA2.
Metcalfe KA; Poll A; Llacuachaqui M; Nanda S; Tulman A; Mian N; Sun P; Narod SA
Clin Genet; 2010 Nov; 78(5):411-7. PubMed ID: 20653694
[TBL] [Abstract][Full Text] [Related]
23. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.
Kauff ND; Mitra N; Robson ME; Hurley KE; Chuai S; Goldfrank D; Wadsworth E; Lee J; Cigler T; Borgen PI; Norton L; Barakat RR; Offit K
J Natl Cancer Inst; 2005 Sep; 97(18):1382-4. PubMed ID: 16174860
[TBL] [Abstract][Full Text] [Related]
24. Communication about genetic testing in families of male BRCA1/2 carriers and non-carriers: patterns, priorities and problems.
Hallowell N; Ardern-Jones A; Eeles R; Foster C; Lucassen A; Moynihan C; Watson M
Clin Genet; 2005 Jun; 67(6):492-502. PubMed ID: 15857416
[TBL] [Abstract][Full Text] [Related]
25. Preventing future cancers by testing women with ovarian cancer for BRCA mutations.
Kwon JS; Daniels MS; Sun CC; Lu KH
J Clin Oncol; 2010 Feb; 28(4):675-82. PubMed ID: 19841329
[TBL] [Abstract][Full Text] [Related]
26. High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriers.
Maehle L; Apold J; Paulsen T; Hagen B; Løvslett K; Fiane B; Van Ghelue M; Clark N; Møller P
Clin Cancer Res; 2008 Nov; 14(22):7569-73. PubMed ID: 19010876
[TBL] [Abstract][Full Text] [Related]
27. BRCA1 genetic mutation and its link to ovarian cancer: implications for advanced practice nurses.
Brunsvold AN; Wung SF; Merkle CJ
J Am Acad Nurse Pract; 2005 Dec; 17(12):518-26. PubMed ID: 16293160
[TBL] [Abstract][Full Text] [Related]
28. Decisions and ethical issues among BRCA carriers and the use of preimplantation genetic diagnosis.
Quinn GP; Vadaparampil ST; Bower B; Friedman S; Keefe DL
Minerva Med; 2009 Oct; 100(5):371-83. PubMed ID: 19910890
[TBL] [Abstract][Full Text] [Related]
29. [Clinical and molecular diagnosis of inherited breast-ovarian cancer].
Chompret A
J Gynecol Obstet Biol Reprod (Paris); 2003 Apr; 32(2):101-19. PubMed ID: 12717301
[TBL] [Abstract][Full Text] [Related]
30. Factors associated with decisions about clinical BRCA1/2 testing.
Armstrong K; Calzone K; Stopfer J; Fitzgerald G; Coyne J; Weber B
Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1251-4. PubMed ID: 11097234
[TBL] [Abstract][Full Text] [Related]
31. Impact of an information booklet on satisfaction and decision-making about BRCA genetic testing.
Mancini J; Noguès C; Adenis C; Berthet P; Bonadona V; Chompret A; Coupier I; Eisinger F; Fricker JP; Gauthier-Villars M; Lasset C; Lortholary A; N'Guyen TD; Vennin P; Sobol H; Stoppa-Lyonnet D; Julian-Reynier C
Eur J Cancer; 2006 May; 42(7):871-81. PubMed ID: 16563745
[TBL] [Abstract][Full Text] [Related]
32. Subjective and objective risk of ovarian cancer in Ashkenazi Jewish women testing for BRCA1/2 mutations.
Kelly KM; Senter L; Leventhal H; Ozakinci G; Porter K
Patient Educ Couns; 2008 Jan; 70(1):135-42. PubMed ID: 17988821
[TBL] [Abstract][Full Text] [Related]
33. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
[TBL] [Abstract][Full Text] [Related]
34. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers.
Metcalfe KA; Lynch HT; Ghadirian P; Tung N; Olivotto IA; Foulkes WD; Warner E; Olopade O; Eisen A; Weber B; McLennan J; Sun P; Narod SA
Gynecol Oncol; 2005 Jan; 96(1):222-6. PubMed ID: 15589605
[TBL] [Abstract][Full Text] [Related]
35. Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.
Kotsopoulos J; Lubinski J; Neuhausen SL; Lynch HT; Rosen B; Ainsworth P; Moller P; Ghadirian P; Isaacs C; Karlan B; Sun P; Narod SA
Gynecol Oncol; 2006 Jan; 100(1):83-8. PubMed ID: 16137751
[TBL] [Abstract][Full Text] [Related]
36. Psychological adjustment among male partners in response to women's breast/ovarian cancer risk: a theoretical review of the literature.
Sherman KA; Kasparian NA; Mireskandari S
Psychooncology; 2010 Jan; 19(1):1-11. PubMed ID: 19472298
[TBL] [Abstract][Full Text] [Related]
37. Surveillance behavior and prophylactic surgery after predictive testing for hereditary breast/ovarian cancer.
Claes E; Evers-Kiebooms G; Decruyenaere M; Denayer L; Boogaerts A; Philippe K; Legius E
Behav Med; 2005; 31(3):93-105. PubMed ID: 16252621
[TBL] [Abstract][Full Text] [Related]
38. Moving into the mainstream: healthcare professionals' views of implementing treatment focussed genetic testing in breast cancer care.
Hallowell N; Wright S; Stirling D; Gourley C; Young O; Porteous M
Fam Cancer; 2019 Jul; 18(3):293-301. PubMed ID: 30689103
[TBL] [Abstract][Full Text] [Related]
39. Patients' Views of Treatment-Focused Genetic Testing (TFGT): Some Lessons for the Mainstreaming of BRCA1 and BRCA2 Testing.
Wright S; Porteous M; Stirling D; Lawton J; Young O; Gourley C; Hallowell N
J Genet Couns; 2018 May; 27(6):1459-72. PubMed ID: 29752676
[TBL] [Abstract][Full Text] [Related]
40. When knowledge of a heritable gene mutation comes out of the blue: treatment-focused genetic testing in women newly diagnosed with breast cancer.
Meiser B; Quinn VF; Gleeson M; Kirk J; Tucker KM; Rahman B; Saunders C; Watts KJ; Peate M; Geelhoed E; Barlow-Stewart K; Field M; Harris M; Antill YC; Mitchell G
Eur J Hum Genet; 2016 Nov; 24(11):1517-1523. PubMed ID: 27329735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
